Coeptis Therapeutics Holdings Future Growth

Future criteria checks 0/6

Coeptis Therapeutics Holdings's earnings are forecast to decline at 13.7% per annum. EPS is expected to grow by 17.8% per annum.

Key information

-13.7%

Earnings growth rate

17.8%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	17 Jun 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqCM:COEP - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	N/A	-12	-7	-7	N/A
6/30/2024	N/A	-16	-7	-7	N/A
3/31/2024	N/A	-16	-7	-7	N/A
12/31/2023	N/A	-21	-7	-7	N/A
9/30/2023	N/A	-20	-6	-6	N/A
6/30/2023	N/A	-20	-5	-5	N/A
3/31/2023	N/A	-26	-5	-5	N/A
12/31/2022	N/A	-38	-4	-4	N/A
9/30/2022	N/A	-37	0	-3	N/A
6/30/2022	N/A	-38	-7	-6	N/A
3/31/2022	N/A	-31	-7	-5	N/A
12/31/2021	0	-13	-6	-4	N/A
9/30/2021	0	-15	-10	-5	N/A
6/30/2021	0	-11	-3	-2	N/A
3/31/2021	0	-9	-2	-2	N/A
12/31/2020	0	-9	-3	-3	N/A
12/31/2019	0	-2	-2	-4	N/A
12/31/2018	0	-2	-1	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: COEP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: COEP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: COEP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if COEP's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if COEP's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if COEP's Return on Equity is forecast to be high in 3 years time

Coeptis Therapeutics Holdings Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Coeptis Therapeutics Holdings, Inc., Annual General Meeting, Dec 18, 2024

Coeptis Therapeutics Holdings, Inc. Announces Results from Phase 1 Study Evaluating DVX201

Nasdaq Hearings Panel Grants Coeptis Therapeutics Holdings' Request for Continued Listing on The Nasdaq Stock Market Through January 15, 2025 to Compliance with Nasdaq Listing Rule 5550(a)(2)

Coeptis Therapeutics Holdings Provides Update on Nasdaq Listing

Coeptis Therapeutics Holdings, Inc. announced delayed 10-Q filing

Coeptis Therapeutics Holdings Provides Non-Compliance Update

Coeptis Therapeutics Holdings, Inc. announced that it has received CAD 4.3 million in funding

Coeptis Therapeutics Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Closing Bid Requirement for Continued Listing on The Nasdaq Capital Market

Coeptis Therapeutics Holdings, Inc., Annual General Meeting, Dec 20, 2023

Coeptis Therapeutics Holdings, Inc., Annual General Meeting, Dec 20, 2023

Coeptis Therapeutics Holdings, Inc. announced that it has received $2 million in funding

Coeptis Therapeutics Holdings, Inc. announced that it expects to receive $2 million in funding

Coeptis Therapeutics Holdings Receives Non-Compliance Letter from Nasdaq

Coeptis Therapeutics Holdings, Inc Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

Coeptis Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering.

Coeptis Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering.

Coeptis Therapeutics Holdings Receives Approval to Transfer to the Nasdaq Capital Market from the Nasdaq Global Select Market

Coeptis Therapeutics Holdings, Inc. Announces CFO Changes

Coeptis Therapeutics Holdings Receives a Letter from the Nasdaq Stock Market LLC

No independent directors

Coeptis Therapeutics Holdings, Inc. Announces Board Appointments

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies